Inventiva Pharma Overview

  • Status
  • Public
  • Employees
  • 105
Employees
  • Stock Symbol
  • IVA
Stock Symbol
  • Share Price
  • $11.13
  • (As of Thursday Closing)

Inventiva Pharma General Information

Description

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France. The majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 50 rue de Dijon
  • 21121 Daix
  • France
+33 03 00 00 00 00

Inventiva Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inventiva Pharma Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.13 $10.95 $10.00 - $15.45 $447M 40.9M 18.9K -$1.50

Inventiva Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 442,147 442,147 507,949 70,370
Revenue 4,959 4,959 424 7,834
EBITDA (57,954) (57,954) (36,352) (32,611)
Net Income (58,683) (58,683) (38,323) (33,827)
Total Assets 138,114 138,114 170,867 63,805
Total Debt 11,457 11,457 12,367 128
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Inventiva Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial

Inventiva Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptor
Drug Discovery
Daix, France
105 As of 2021
00000
00000000 00000

000000 0

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
000000000000000
Ardsley, NY
000 As of 0000
00000
0.00 0000-00-00
000000&0

0000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inventiva Pharma Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acorda Therapeutics Formerly VC-backed Ardsley, NY 000 00000 000000&0
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
00000 000000000000 Corporation Exton, PA 00 00000 000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
You’re viewing 5 of 48 competitors. Get the full list »

Inventiva Pharma Patents

Inventiva Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210137937-A1 Method of treatment of cirrhosis Pending 08-Nov-2019 00000000
AU-2019352009-A1 Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer Pending 02-Oct-2018 000000000
CA-3114375-A1 Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer Pending 02-Oct-2018 000000000
EP-3632908-A1 Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer Withdrawn 02-Oct-2018 0000000000 00
US-20210323982-A1 Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer Pending 02-Oct-2018 C07F5/025
To view Inventiva Pharma’s complete patent history, request access »

Inventiva Pharma Executive Team (7)

Name Title Board Seat Contact Info
Frédéric Cren Co-Founder, Chief Executive Officer and Chairman
Jean Volatier Chief Financial Officer, Finance
Pierre Broqua Ph.D Chief Scientific Officer & Founder
Alice Roudot-Ketelers Vice President
Michael Cooreman MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Inventiva Pharma Board Members (6)

Name Representing Role Since
000000 00000000 00.0 Self Board Member 000 0000
00000 00000 Self Board Member 000 0000
00é0é000 0000 Inventiva Pharma Co-Founder, Chief Executive Officer and Chairman 000 0000
00000 000000 Self Board Member 000 0000
0000 00 00 Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Inventiva Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inventiva Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial